StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
July 12, 2018 8:01 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
July 12, 2018 8:00 AM
Seattle Genetics (SGEN) Reports Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
July 11, 2018 8:02 AM